Barely Significant
← all phrases

“a nonsignificant trend”

5,407 sentences · 5,407 papers · 7,516 search hits before verification · confirmed specimen

Sighted at

p<0.1

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

a nonsignificant trendP = 0.0581.2× alphagold
With regard to satisfaction with facial appearance (SWAP), patients also reported early postsurgical increase in satisfaction with facial appearance from baseline to 3 months postsurgery (t = 3.56; df = 11; P = 0.004); and sustained increase (baseline to 6 months postsurgery) (t = 2.45; df = =11; P = 0.032); followed by a nonsignificant trend for increased satisfaction from baseline to 9 months postsurgery (t = 2.14; df = 11; P = 0.058).
a nonsignificant trendp = 0.0581.2× alphagold
Serum sodium concentration increased significantly from the beginning to the end of exercise in both MOD and HI sessions (time effect: p = 0.003) and decreased during recovery (time effect: p < 0.0001), with a nonsignificant trend towards higher serum sodium in MOD versus HI during both exercise (treatment effect: p = 0.058, interaction: p = 0.62) and recovery (treatment effect: p = 0.08, interaction: p = 0.56) ( Figure 1 C).
a nonsignificant trendp = 0.0581.2× alphagold
Brain Cell Densities Between Sexes Large and small males differed in the scaling relationship between brain mass and CB density ( F = 8.16, df = 14, p = 0.0045), with a nonsignificant trend towards difference in OL cell density ( F = 3.52, df = 14, p = 0.058) and total brain cell density ( F = 3.17, df = 14, p = 0.073).
a nonsignificant trendp=0.0581.2× alphagold
In stratified analysis, decreased percent-predicted post-bronchodilator FEV1 (aOR, 1.39; 95% CI, 1.05 to 1.85 per 10%pred decrease) and ICS-containg inhalers (aOR, 4.01; 95% CI, 1.61 to 9.95) predicted progression among patients with eosinophils <300/μL, while higher eosinophils ≥300/μL showed a nonsignificant trend (aOR, 1.16; 95% CI, 1.00 to 1.36; p=0.058).
a nonsignificant trendP = .0581.2× alphagold
Exploratory End Points Lean body mass/fat mass ratio was increased significantly in the DCCR group compared to the placebo group (see Table 2 ; P = .001), with a significant reduction in body fat mass in the DCCR group compared to the placebo group (see Table 2 ; P = .003) and a nonsignificant trend toward an increase in lean body mass (see Table 2 ; P = .058).
a nonsignificant trendp = 0.0581.2× alphagold
In the GERD group, mean fluorescence intensity of immunodominant donor-specific antibodies (DSAs) was significantly increased at M6 and M12, as compared to day 0 (M6 vs day 0, p < 0.0001, and M12 vs day 0, p = 0.003, respectively), whereas in noGERD patients, only a nonsignificant trend toward an increase of immunodominant DSAs was observed at M6 (M6 vs day 0, p = 0.058), without difference at M12 (M12 vs day 0, p = 0.42, respectively) ( Table 2 ).